

**January 27, 2025**

**Four Drugs to be added to High-Cost Specialty Drugs (BIO) Reinsurance coverage.**

AHCCCS is pleased to announce the addition of the following drugs to the High-Cost Specialty Drug Reinsurance effective 10/01/2024:

**Miplyffa** (arimoclomol) is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

**Aqneursa** (levacetylleucine) is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.

**Joenja** (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

**Voxzogo** (vosoritide) is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

The Request for Catastrophic Reinsurance letter on the AHCCCS website will be updated with the new high-cost specialty drugs in the next few days. If your plan has a member that has been on one of the newly effective high-cost specialty drugs, AHCCCS Medical Management will retroactively authorize to 10/1/24, however the request must be submitted before 03/01/2025.